CA3260354A1 - Monoclonal Antibodies Against SLC34A2 and Their Uses - Google Patents

Monoclonal Antibodies Against SLC34A2 and Their Uses

Info

Publication number
CA3260354A1
CA3260354A1 CA3260354A CA3260354A CA3260354A1 CA 3260354 A1 CA3260354 A1 CA 3260354A1 CA 3260354 A CA3260354 A CA 3260354A CA 3260354 A CA3260354 A CA 3260354A CA 3260354 A1 CA3260354 A1 CA 3260354A1
Authority
CA
Canada
Prior art keywords
slc34a2
monoclonal antibodies
monoclonal
antibodies
slc34a2 monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3260354A
Other languages
English (en)
French (fr)
Inventor
Runsheng Li
Wentao Huang
Yifan Li
Original Assignee
LaNova Medicines Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LaNova Medicines Development Co Ltd filed Critical LaNova Medicines Development Co Ltd
Publication of CA3260354A1 publication Critical patent/CA3260354A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3260354A 2022-06-22 2023-06-21 Monoclonal Antibodies Against SLC34A2 and Their Uses Pending CA3260354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022100315 2022-06-22
CNPCT/CN2022/100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3260354A1 true CA3260354A1 (en) 2023-12-28

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3260354A Pending CA3260354A1 (en) 2022-06-22 2023-06-21 Monoclonal Antibodies Against SLC34A2 and Their Uses

Country Status (14)

Country Link
US (2) US12215150B2 (cg-RX-API-DMAC10.html)
EP (1) EP4543926A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025520692A (cg-RX-API-DMAC10.html)
KR (1) KR20250051643A (cg-RX-API-DMAC10.html)
CN (1) CN119948054A (cg-RX-API-DMAC10.html)
AU (1) AU2023289743A1 (cg-RX-API-DMAC10.html)
CA (1) CA3260354A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024004012A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024017740A2 (cg-RX-API-DMAC10.html)
IL (1) IL317849A (cg-RX-API-DMAC10.html)
MX (1) MX2025000053A (cg-RX-API-DMAC10.html)
PE (1) PE20252048A1 (cg-RX-API-DMAC10.html)
TW (1) TW202409076A (cg-RX-API-DMAC10.html)
WO (1) WO2023246879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024408814A1 (en) * 2023-12-21 2026-07-09 LaNova Medicines Limited Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US20250154248A1 (en) 2025-05-15
EP4543926A1 (en) 2025-04-30
CN119948054A (zh) 2025-05-06
JP2025520692A (ja) 2025-07-03
IL317849A (en) 2025-02-01
US12215150B2 (en) 2025-02-04
CO2024017740A2 (es) 2025-05-19
KR20250051643A (ko) 2025-04-17
MX2025000053A (es) 2025-04-02
US20240301052A1 (en) 2024-09-12
TW202409076A (zh) 2024-03-01
WO2023246879A1 (en) 2023-12-28
CL2024004012A1 (es) 2025-05-02
PE20252048A1 (es) 2025-08-21
AU2023289743A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
EP4274851A4 (en) MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF
CA3265264A1 (en) CCR8 ANTIBODIES AND THEIR USES
CA3266237A1 (en) Anti-SARS-CoV-2 antibodies and their uses
CA3254156A1 (en) Anti-CD84 antibodies and their uses
IL317849A (en) Anti-SLC34A2 monoclonal antibodies and their uses
CA3260932A1 (en) CD25-SPECIFIC ANTIBODIES AND THEIR USES
CA3299227A1 (en) Sarbecovirus monoclonal antibodies and uses thereof
CA3275669A1 (en) Anti-slc1a4 monoclonal antibodies and uses thereof
HK40076679A (en) Anti-ccr8 monoclonal antibodies and uses thereof
CA3269810A1 (en) Anti-asgr1 monoclonal antibody and use thereof
AU2023902248A0 (en) Humanised antibodies and uses thereof
AU2025900632A0 (en) Humanized anti-KRT14 antibodies and uses thereof
EP4296358A4 (en) MONOCLONAL ANTI-TETRANOR-PGDM ANTIBODY AND USE THEREOF
CA3310135A1 (en) Cd40-targetting antibodies and uses thereof
CA3306831A1 (en) Anti-alpha-synuclein antibodies and uses thereof
CA3307613A1 (en) Anti-ny-eso-1 antibodies and uses thereof
CA3307647A1 (en) Anti-il-4ra antibodies and uses thereof
CA3304852A1 (en) Anti-tigit antibodies and uses thereof
CA3305834A1 (en) Anti-cdh17 antibodies and uses thereof
CA3304830A1 (en) Anti-tdp-43 antibodies and uses thereof
CA3303332A1 (en) Anti-ly6 antibodies and uses thereof
CA3299540A1 (en) Anti-b7-h3 antibodies and uses thereof
CA3299545A1 (en) Anti-acvr2b antibodies and uses thereof
AU2024312447A1 (en) Anti-klrg1 antibodies and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241220

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250330

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250401

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250410

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250521

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401